The FDA is expected to make a decision on Thursday that could affect more than six million people over the age of 65 who are battling Alzheimer’s disease in the US.
Leqembi received preliminary approval in January and would be the first drug intended to slow the progression of Alzheimer’s disease.
A clinical trial showed that the drug reduced the rate of cognitive decline by 27% in an 18-month study involving people in the early stage of Alzheimer’s disease.
It remains to wait for the potential cost to patients and how much Medicare might cover.
